Health authorities have moved to allay public fears over the availability of Nevirapine, a critical antiretroviral medication used in the treatment of HIV. The drug, primarily administered in combination with other therapies, is also essential in preventing mother-to-child transmission of HIV.
It has been confirmed that the molecule Nevirapine is in adequate supply across the country, including in key referral facilities. Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), works by reducing the viral load in a patient’s bloodstream, thereby slowing the progression of HIV and improving health outcomes for individuals living with the virus.
Contrary to recent concerns suggesting a potential shortage, health officials have reassured citizens that all health facilities, including those in Kisumu County and major hospitals such as the Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), are sufficiently stocked. In Kisumu, the drug is reportedly available in quantities that can sustain the local demand for at least seven months. This statement follows claims that some regions were running low on pediatric Nevirapine, a version specifically formulated for children.
Officials reiterated that there is no cause for alarm, emphasizing that medical facilities nationwide continue to receive timely and adequate supplies of Nevirapine. The Kenya Medical Supplies Authority (Kemsa), which manages drug distribution logistics across the country, reportedly has more stocks of the drug and continues to replenish supplies routinely.
The clarification was made during a health event marking World Blood Donor Day in Samburu County. It aimed to calm fears sparked by speculation linking the supposed shortage to recent changes in foreign health funding. These concerns emerged after the United States announced adjustments to its USAID-funded health support programs, raising questions about their potential impact on essential drug supplies and HIV care services.
In response to these concerns, authorities affirmed that these funding changes would not interfere with HIV service delivery in Kenya. Additionally, it was confirmed that all data concerning HIV and sexually transmitted infections is securely stored on government-controlled servers. This data is only accessible by authorized personnel, ensuring that patient privacy and confidentiality remain protected.
Furthermore, the public was urged to seek clarification and accurate information directly from the Ministry of Health when dealing with health-related matters. It was emphasized that misinformation can undermine public trust and cause unnecessary panic, especially when it concerns life-saving medications.
Overall, the assurance provided reinforces the government’s commitment to uninterrupted HIV care and the continued prioritization of public health, despite external financial shifts.
